Revised labeling approved for Cypher stent

January 30, 2006

A retrospective analysis by the FDA of more than 900 patients has found no increased risk of myocardial infarction with the use of overlapping Cypher stents (sirolimus-eluting coronary stent, Cordis Corp.), leading the agency to approve revised labeling for the product. Overlapping stents are used in patients with complex coronary artery disease when the blockage is too long for a single stent. Approximately 25% of procedures involve overlapping stents. The new labeling can be found at

A retrospective analysis by the FDA of more than 900 patients has found no increased risk of myocardial infarction with the use of overlapping Cypher stents (sirolimus-eluting coronary stent, Cordis Corp.), leading the agency to approve revised labeling for the product. Overlapping stents are used in patients with complex coronary artery disease when the blockage is too long for a single stent. Approximately 25% of procedures involve overlapping stents. The new labeling can be found at http://www.cypherusa.com/.